Hepcidin Agents Set to Improve Polycythemia Vera Care Protagonist Therapeutics earlier this month reported positive results from its phase III VERIFY study of hepcidin mimetic rusfertide for th...

#Hepcidin agents set to improve #PolycythemiaVera care (blog): rnaitherapeutics.blogspot.com/2025/03/hepc...

$PTGX $SLN $IONS #rusfertide #divesiran #sapablursen

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update LONDON, February 27, 2025--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported ...

$SLN to focus cash on #divesiran for #polycythemiavera. Enrolment in p2 to be complete in 2025.

Progression of #zerlasiran for Lpa lowering into p3 (as expected) pending partnership.

Cash runway into 2027.

$PTGX

finance.yahoo.com/news/silence...